Tyrosine Kinase Inhibitors

Most Exhaustive Report

Tyrosine Kinase Inhibitors - Pipeline Insights 2018

Tyrosine Kinase Inhibitors

Most Exhaustive Report

Tyrosine Kinase Inhibitors - Pipeline Insights 2018

SKU : APA17807 Published on : February 2018 Pages : 70


Get 10% Free Customization
On This Report.
Customize this report Enquire before buying
data center market research

Get actionable insights on how COVID-19 is impacting your business sector.

Enquire now

Tyrosine Kinase Pharma Pipeline Insights

Tyrosine kinases are a subclass of protein kinase. Tyrosine kinases play a central role in signal transduction that ultimately affects gene transcription within the nucleus. These molecules are considered as pivotal points of functional cellular pathways as they control cell cycle, proliferation, differentiation, and cell death or survival. Tyrosine kinases are primarily classified as receptor tyrosine kinase (RTK) which inlcude EGFR, PDGFR, FGFR and the IR and non-receptor tyrosine kinase (NRTK) which include SRC, ABL, FAK and Janus kinase. Disruption in tyrosine kinase pathway is implicated in several malignancies and thus tyrosine kinase inhibitors, targeted drug molecules inhibiting tyrosine kinase activity, are considered as a key therapeutic class. Few of the key marketed tyrosine kinase inhibitors include Dasatinib (Sprycel), Erlotinib (Tarceva), Gefitinib (Iressa), Imatinib (Gleevec). Lapatinib (Tykerb), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent).

Over the past two decades, research studies have proved its efficacy for mitigation and control of non-cancerous diseases too. Thus research activity on use of inhibitors for various diseases such as Parkinson's disease and chronic obstructive pulmonary disorder is gradually increasing. The growing availability of these agents has enabled the pharmaceutical companies to develop new combination molecules which have the capacity to provide greater insight into the body’s acceptance of inhibitors so as to develop more effective therapies.

More recently, few molecules have been developed that inhibits tyrosine kinase these agents are in various stages of clinical development. The tyrosine kinase inhibitors pipeline has more than 15 molecules and is expected to achieve the regulatory approval in the near future, few of which are Oncoprex (CNVN202), ORS-1006, JNJ 49095397, RV-568, AP32788, APTO-500, and transtinib. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage. Few of the companies which are involved in the development of tyrosine kinase inhibitor include IL-Yang Pharm, SRI, Sareum, Genprex, Arrien, J&J, and Takeda.

Reasons to Buy

  • To gain erudite insights about the Tyrosine Kinase inhibitor pipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation


Client Speak

data center market size

Erik Young

CEO, Co-founder
Audink Inc., DBA Audios

The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.

data center market

Benjamin Arnold

Senior Product Manager

I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Arizton’s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.

data center market research

Hallmann, Nickolai

Manager Market Analyst Power
Generation & Energy
Rolls-Royce Power Systems AG

The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.

Customer Service



Copyright 2019 - Arizton

data center market